Cystic fibrosis (CF) is an autosomal recessive disease that affects many organ systems, most notably the pulmonary and gastrointestinal systems. Through genome-wide association studies, multiple genetic regions modifying CF-related pulmonary and gastrointestinal symptoms have been identified, but translation of these findings to clinical benefit remains elusive. Symptom variation in CF patients has been associated with changes in health-related quality of life (HRQOL), but the relationship between CF symptom-modifying genetic loci and HRQOL has not been explored. The purpose of this study was to determine whether two previously identified genetic modifiers of CF-related pathology also modify the subscales of HRQOL.
Methods:
HRQOL and genotype data were obtained and analyzed. Linear regressions were used to examine the amount of variance in HRQOL subscales that could be explained by genotype for each modifier locus.
Results:
A significant regression equation was found between genotype for rs5952223, a variant near chrXq22-q23, and emotional functioning in a sample of 129 CF patients.
Discussion:
These data suggest that genotype for this single-nucleotide polymorphism is associated with emotional functioning in CF patients and highlight this genetic region as a potential therapeutic target, irrespective of CF transmembrane conductance regulator genotype.
BoukaA.TiedeH.LiebichL.DumitrascuR.HeckerC.ReichenbergerF.MayerK.SeegerW.SchulzR. (2012). Quality of life in clinically stable adult cystic fibrosis out-patients: Associations with daytime sleepiness and sleep quality. Respiratory Medicine, 106(9), 1244–1249. https://doi.org/10.1016/j.rmed.2012.06.010
3.
CorvolH.BlackmanS. M.BoelleP. Y.GallinsP. J.PaceR. G.StonebrakerJ. R.AccursoF. J.ClementA.CollacoJ. M.DangH.DangA. T.FrancaA.GongJ.GuillotL.KeenanK.LiW.LinF.PatroneM. V.RaraighK. S.SunL.KnowlesM. R. (2015). Genome-wide association meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosis. Nature Communications, 6, 8382. https://doi.org/10.1038/ncomms9382
4.
CorvolH.ThompsonK. E.TabaryO.le RouzicP.GuillotL. (2016). Translating the genetics of cystic fibrosis to personalized medicine. Translational Research, 168, 40–49. https://doi.org/10.1016/j.trsl.2015.04.008
5.
CronlyJ. A.DuffA. J.RiekertK. A.FitzgeraldA. P.PerryI. J.LehaneE. A.HorganA.HoweB. A.Ni ChroininM.SavageE. (2018). Health-related quality of life in adolescents and adults with cystic fibrosis: Physical and mental health predictors. Respiratory Care, 64, 406–415. https://doi.org/10.4187/respcare.06356
6.
DarrahR. J.JaconoF. J.JoshiN.MitchellA. L.SattarA.CampanaroC. K.LitmanP.FreyJ.NetheryD. E.BarbatoE. S.HodgesC. A.CorvolH.CuttingG. R.KnowlesM. R.StrugL. J.DrummM. L. (2019). AGTR2 absence or antagonism prevents cystic fibrosis pulmonary manifestations. Journal of Cystic Fibrosis, 18(1), 127–134. https://doi.org/10.1016/j.jcf.2018.05.013
7.
DillE. J.DawsonR.SellersD. E.RobinsonW. M.SawickiG. S. (2013). Longitudinal trends in health-related quality of life in adults with cystic fibrosis. Chest, 144(3), 981–989. https://doi.org/10.1378/chest.12-1404
8.
DongY. F.KataokaK.ToyamaK.SuetaD.KoibuchiN.YamamotoE.YataK.TomimotoH.OgawaH.Kim-MitsuyamaS. (2011). Attenuation of brain damage and cognitive impairment by direct renin inhibition in mice with chronic cerebral hypoperfusion. Hypertension, 58(4), 635–642. https://doi.org/10.1161/HYPERTENSIONAHA.111.173534
9.
FuchtemeierM.BrinckmannM. P.FoddisM.KunzA.PoC.CuratoC.DirnaglU.FarrT. D. (2015). Vascular change and opposing effects of the angiotensin type 2 receptor in a mouse model of vascular cognitive impairment. Journal of Cerebral Blood Flow & Metabolism, 35(3), 476–484. https://doi.org/10.1038/jcbfm.2014.221
10.
GundogduU.FisN. P.EralpE. E.KaradagB. T. (2019). Major depression and psychiatric comorbidity in Turkish children and adolescents with cystic fibrosis. Pediatric Pulmonology, 54(12), 1927–1935. https://doi.org/10.1002/ppul.24492
11.
HavermansT.ColpaertK.VanharenL.DupontL. J. (2009). Health related quality of life in cystic fibrosis: To work or not to work?Journal of Cystic Fibrosis, 8(3), 218–223. https://doi.org/10.1016/j.jcf.2009.03.002
12.
HavermansT.WillemL. (2019). Prevention of anxiety and depression in cystic fibrosis. Current Opinion in Pulmonary Medicine, 25(6), 654–659. https://doi.org/10.1097/MCP.0000000000000617
13.
HolguinF. (2018). Triple CFTR modulator therapy for cystic fibrosis. New England Journal of Medicine, 379(17), 1671–1672. https://doi.org/10.1056/NEJMe1811996
14.
IwanamiJ.MogiM.TsukudaK.JingF.OhshimaK.WangX. L.NakaokaH.Kan-noH.ChisakaT.BaiH. Y.MinL. J.HoriuchiM. (2014). Possible synergistic effect of direct angiotensin II Type 2 receptor stimulation by compound 21 with memantine on prevention of cognitive decline in Type 2 diabetic mice. European Journal of Pharmacology, 724, 9–15. https://doi.org/10.1016/j.ejphar.2013.12.015
15.
KmitA.MarsonF. A. L.PereiraS. V.VinagreA. M.LeiteG. S.ServidoniM. F.RibeiroJ. D.RibeiroA. F.BertuzzoC. S.AmaralM. D. (2019). Extent of rescue of F508del-CFTR function by VX-809 and VX-770 in human nasal epithelial cells correlates with SNP rs7512462 in SLC26A9 gene in F508del/F508del cystic fibrosis patients. Biochimica et Biophysica Acta Molecular Basis of Disease, 1865(6), 1323–1331. https://doi.org/10.1016/j.bbadis.2019.01.029
16.
KraynackN. C.GothardM. D.FallettaL. M.McBrideJ. T. (2011). Approach to treating cystic fibrosis pulmonary exacerbations varies widely across US CF care centers. Pediatric Pulmonology, 46(9), 870–881. https://doi.org/10.1002/ppul.21442
17.
KraynackN. C.McBrideJ. T. (2009). Improving care at cystic fibrosis centers through quality improvement. Seminars in Respiratory and Critical Care Medicine, 30(5), 547–558. https://doi.org/10.1055/s-0029-1238913
18.
LamA. N.AksitM. A.Vecchio-PaganB.SheltonC. A.OsorioD. L.AnzmannA. F.GoffL. A.WhitcombD. C.BlackmanS. M.CuttingG. R. (2019). Increased expression of anion transporter SLC26A9 delays diabetes onset in cystic fibrosis. Journal of Clinical Investigation, 130(1), 272–286. https://doi.org/10.1172/JCI129833
19.
O’NealW. K.KnowlesM. R. (2018). Cystic fibrosis disease modifiers: Complex genetics defines the phenotypic diversity in a monogenic disease. Annual Review of Genomics and Human Genetics, 19, 201–222. https://doi.org/10.1146/annurev-genom-083117-021329
20.
PereiraS. V. N.RibeiroJ. D.BertuzzoC. S.MarsonF. A. L. (2018). Interaction among variants in the SLC gene family (SLC6A14, SLC26A9, SLC11A1, and SLC9A3) and CFTR mutations with clinical markers of cystic fibrosis. Pediatric Pulmonology, 53(7), 888–900. https://doi.org/10.1002/ppul.24005
21.
QuittnerA. L.SawickiG. S.McMullenA.RasouliyanL.PastaD. J.YeginA.KonstanM. W. (2012). Psychometric evaluation of the cystic fibrosis questionnaire-revised in a national sample. Quality of Life Research, 21(7), 1267–1278. https://doi.org/10.1007/s11136-011-0036-z
22.
RommensJ. M.IannuzziM. C.KeremB.DrummM. L.MelmerG.DeanM.RozmahelR.ColeJ. L.KennedyD.HidakaN.CollinsF. S. (1989). Identification of the cystic fibrosis gene: Chromosome walking and jumping. Science, 245(4922), 1059–1065. https://doi.org/10.1126/science2772657
23.
SherryS. T.WardM. H.KholodovM.BakerJ.PhanL.SmigielskiE. M.SirotkinK. (2001). dbSNP: The NCBI database of genetic variation. Nucleic Acids Research, 29(1), 308–311. https://doi.org/10.1093.nar/29.1.308
24.
SoleA.OlveiraC.PerezI.HervasD.ValentineV.Baca YepezA. N.OlveiraG.QuittnerA. L. (2017). Development and electronic validation of the revised cystic fibrosis questionnaire (CFQ-R Teen/Adult): New tool for monitoring psychosocial health in CF. Journal of Cystic Fibrosis, 17, 672–679. https://doi.org/10.1016/j.jcf.2017.10.015
25.
SoleA.PerezI.VazquezI.PastorA.EscrivaJ.SalesG.HervásD.GlanvilleA. R.QuittnerA. L. (2016). Patient-reported symptoms and functioning as indicators of mortality in advanced cystic fibrosis: A new tool for referral and selection for lung transplantation. Journal of Heart and Lung Transplantation, 35(6), 789–794. https://doi.org/10.1016/j.healun.2016.01.1233
26.
SolemC. T.Vera-LlonchM.LiuS.BottemanM.CastiglioneB. (2016). Impact of pulmonary exacerbations and lung function on generic health-related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes, 14, 63. https://doi.org/10.1186/s12955-016-0465-z
27.
SunL.RommensJ. M.CorvolH.LiW.LiX.ChiangT. A.LinF.DorfmanR.BussonP. F.ParekhR. V.ZelenikaD.BlackmanS. M.CoreyM.DoshiV. K.HendersonL.NaughtonK. M.O’NealW. K.PaceR. G.StonebrakerJ. R.WoodS. D.StrugL. J. (2012). Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis. Nature Genetics, 44(5), 562–569. https://doi.org/10.1038/ng.2221
28.
TalwalkarJ. S.KoffJ. L.LeeH. B.BrittoC. J.MulenosA. M.GeorgiopoulosA. M. (2017). Cystic fibrosis transmembrane regulator modulators: Implications for the management of depression and anxiety in cystic fibrosis. Psychosomatics, 58(4), 343–354. https://doi.org/10.1016/j.psym.2017.04.001
29.
TruettG. E.HeegerP.MynattR. L.TruettA. A.WalkerJ. A.WarmanM. L. (2000). Preparation of PCR-quality mouse genomic DNA with hot sodium hydroxide and tris (HotSHOT). Biotechniques, 29(1), 52–54. https://doi.org/10.2144/00291bm09
30.
UchmanowiczI.Jankowska-PolanskaB.RosinczukJ.WleklikM. (2015). Health-related quality of life of patients suffering from cystic fibrosis. Advances in Clinical and Experimental Medicine, 24(1), 147–152. https://doi.org/10.17219/acem/38147
31.
VervoortV. S.BeachemM. A.EdwardsP. S.LaddS.MillerK. E.de MolleratX.ClarksonK.DuPontB.SchwartzC. E.StevensonR. E.BoydE.SrivastavaA. K. (2002). AGTR2 mutations in X-linked mental retardation. Science, 296(5577), 2401–2403. https://doi.org/10.1126/science.1072191
32.
VervoortV. S.GuzauskasG.ArchieJ.SchwartzC. E.StevensonR. E.SrivastavaA. K. (2006). AGTR2 in brain development and function. American Journal of Medical Genetics—Part A, 140(5), 419–420. https://doi.org/10.1002/ajmg.a.31046
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
